4D Molecular Therapeutics (FDMT) Net Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Net Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -185.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -763.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 529.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4,168.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 673.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2,208.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -392.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,636.00 |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | 36.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.25 Mn |
| Mar 31, 2026 | 34.04 Mn |
| Dec 31, 2025 | 496.71 Mn |
| Sep 30, 2025 | 139.82 Mn |
| Jun 30, 2025 | 33.47 Mn |
| Mar 31, 2025 | -22.69 Mn |
| Dec 31, 2024 | -513.70 Mn |
| Sep 30, 2024 | -146.14 Mn |
| Jun 30, 2024 | -68.67 Mn |
| Mar 31, 2024 | -10.61 Mn |
| Dec 31, 2023 | 17.21 Mn |
| Sep 30, 2023 | 508,744.00 |
| Jun 30, 2023 | 494,541.00 |
| Mar 31, 2023 | -746,421.00 |
| Dec 31, 2022 | 2.51 Mn |
| Sep 30, 2022 | -351,016.00 |
| Jun 30, 2022 | -1.73 Mn |
| Mar 31, 2022 | -134,032.00 |
| Dec 31, 2021 | -2.94 Mn |
| Sep 30, 2021 | -152,249.00 |